Mode
Text Size
Log in / Sign up
N/A N=69 Randomized Triple-blind Supportive Care

Dorsal Root Ganglion Thermal Radiofrequency Versus Pulsed Radiofrequency for Metastatic Pain in Thoracic Vertebral Body

Bone Neoplasm,Malignant Vertebral Column Thoracic Secondary

Enrolled (actual)
69
Serious AEs
0.0%
Results posted
Jul 2020
Primary outcome: Primary: The European Organisation for Research and Treatment of Cancer (EORTC) Questionnaire to Measure Change in the Intensity of Pain QLQ-C30 — 41.30; 51.08; 38.76; 42.48 score on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
PRF on DRG (Device); TRF on DRG (Device); Corticosteroid injection (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
National Cancer Institute, Egypt
Primary completion
Jul 2018

Outcome Measures

OutcomeResultp-value
PRIMARY
The European Organisation for Research and Treatment of Cancer (EORTC) Questionnaire to Measure Change in the Intensity of Pain QLQ-C30
41.30; 51.08; 38.76; 42.48; 46.53; 54.96
PRIMARY
EORTC QLQ-BM22
50.43; 35.07; 44.36; 41.54; 30.41; 34.75
PRIMARY
Visual Analog Scale (VAS), to Evaluate Pain
68.57; 48.78; 66.17
PRIMARY
Oswestry Low Back Pain Disability Questionnaire (ODI),
62.52; 52.87; 61.61
SECONDARY
Number of Participants With Any Complications
0; 7; 1
SECONDARY
To Measure Change in Analgesic Usage
4.30; 4.57; 3.87; 3.43; 2.70; 3.52
SECONDARY
Patients' Satisfaction, Descriptive Scale
1; 16; 0; 5; 2; 6

Summary

AIM OF THE WORK To evaluate the effectiveness and safety of Pulsed and Thermal Radiofrequency lesion of the dorsal root ganglion (RF-DRG) on a consecutive group of patients presenting with chronic thoracic pain due to vertebral bone metastasis.

Eligibility Criteria

Inclusion Criteria

  • A greater than 6-month history of segmental pain of thoracic vertebral body metastasis origin.
  • Unsatisfactory pain control with oral pharmacotherapy including strong opioid with VAS >5 .
  • Absence of a chronic or progressive motor deficit.
  • Absence of significant sensory deficit.
  • No indication for percutaneous or open surgical intervention.
  • Magnetic resonance imaging and Computed Tomogrophy evidence of thoracic involvement.
  • ASA status of II to III .
  • Age > 18 .
  • Body mass index (BMI) : less than forty and more than twenty .
  • Informed consent

Exclusion Criteria

  • Known sensitivity or contraindication to injected materials: local anesthetics.
  • History of psychological disorders.
  • Evidence of significant neurological deficit.
  • Inability to lie prone.
  • Local contraindication to procedure e.g. local sepsis at the site of intervention, coagulopathy.
  • Patient refusal.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03204942). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search